New developments in inhaled corticosteroids

Allergy and Asthma Proceedings

Volumn 27, Issue 5, 2006, Pages 332-340

  Colice, Gene L ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; HUMANS; LUNG; RANDOMIZED CONTROLLED TRIALS;

EID: 33750308452     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2006.27.2929     Document Type: Conference Paper

References (62)

1. Expert Panel II. Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program. February 1997.
2. British guideline on the management of asthma. Thorax 52:i1-i94, 2003.
3. Boulet LP, Becker A, Berube D, et al. Canadian asthma consensus report, 1999. CMAJ 161:S1-S61, 1999.
4. National Asthma Campaign Australia. Asthma Management Handbook 1998.
5. Laitinen LA, Laitinen A, and Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 147:697-704, 1993.
6. Vignola AM, Chanez P, Campbell AM, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 157:403-409, 1998.
7. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 100:44-51, 1997.
8. Carroll N, Elliot J, Morton A, and James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 147:405-410, 1993.
9. Busse WW, and LeManske RF. Asthma. N Engl J Med 344:350-362, 2001.
10. Dorman SC, Sehmi R, Gauvreau GM, et al. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med 169:565-572, 2004.
11. Wood LJ, Sehmi R, Dorman SC, et al. Allergen-induced increases in bone marrow T lymphocytes and interleukin-5 expression in subjects with asthma. Am J Respir Crit Care Med 166:883-889, 2004.
12. Barnes PJ, Pedersen S, and Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 157:51-353, 1998.
13. 2- agonist, terbutaline, on airway inflammation in newly diagnosed asthma. J Allergy Clin Immunol 90:32-42, 1992.
14. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 150:17-22, 1994.
15. Djukanovic R, Wilson JW, Britten KM, et al. Effects of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 148:669-674, 1992.
16. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? Am J Respir Crit Care Med 170:836-844, 2004.
17. Sin DD, and Man SFP. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med 162:1591-1595, 2002.
18. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 277:887-891, 1997.
19. Suissa S, and Ernst P. Inhaled corticosteroids: Impact on asthma morbidity and mortality. J Allergy Clin Immunol 107:937-944, 2001.
20. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343:332-336, 2000.
21. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: Past lessons and future issues. J Allergy Clin Immunol 112:S1-S40, 2003.
22. Lawrence M, Wolf J, Webb DR, et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not systemic activity. Am J Respir Crit Care Med 156:744-751, 1997.
23. Leach CL, Davidson PJ, and Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared to CFC-beclomethasone. Eur J Respir Dis 12:1346-1353, 1998.
24. Leach CL, Davidson PJ, Hasselquist BE, et al. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone. Chest 122:510-516, 2002.
25. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 104:1215-1222, 1999.
26. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways. J Allergy Clin Immunol 104:S258-S267, 1999.
27. Bergeron C, Hauber H, Gotfried, M, et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: Effect of hydrofluoroalkane. J Allergy Clin Immunol 116:983-989, 2005.
28. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane fluisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 87: 405-411, 2001.
29. Shafazand S, and Colice G. Flunisolide HFA for the treatment of asthma: An old friend reformulated. Expert Opin Pharmacother 5:1163-1173, 2004.
30. Silva G, Sherrill DL, Guerra S, et al. Asthma as a risk factor for COPD in a longitudinal study. Chest 126:59-65, 2004.
31. Behrendt C. Mild and moderate-to-severe COPD in nonsmokers. Chest 128:1239, 2005.
32. Limb SL, Brown KC, Wood RA, et al. Irreversible lung function deficits in young adults with a history of childhood asthma. J Allergy Clin Immunol 116:1213-1219, 2005.
33. Selroos O, Pietinalho A, Lofroos A, et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 108: 1228-1234, 1995.
34. Pelaia G, Vatrella A, Cuda G, et al. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci 72:1549-1561, 2003.
35. Vachier I, Chiappara G, Vignola M, et al. Glucocorticoid receptors in bronchial epithelial cells in asthma. Am J Respir Crit Care Med 158:963-970, 1998.
36. Colice GL. Comparing inhaled corticosteroids. Respir Care 45: 846-853, 2000.
37. Smith CL, and Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim-Forsch 48:956-960, 1998.
38. Stellato C, Atsuta J, Bickel CA, et al. An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol 104:623-629, 1999.
39. Aksoy MO, Li X, Borenstein M, Yi Y, et al. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J Allergy Clin Immunol 103:1081-1091, 1999.
40. Szefler SJ, Martin ARJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109:410-418, 2002.
41. Winkler J, Hochhaus G, and Derendorf H. How the lung handles drugs. Proc Am Thorac Soc 1:356-362, 2004.
42. Harrison LI, Colice GL, Donnell D, et al. Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate. J Pharm Pharmacol 51:263-269, 1999.
43. Holz O, Zuhlke I, Einhaus M, et al. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA-vs CFC-driven aerosols. Pulm Pharmacol Ther 17:233-238, 2004.
44. Fuller R, Johnson M, and Bye A. Fluticasone propionate-An update on preclinical and clinical experience. Respir Med 89: S3-S18, 1995.
45. Esmailpur N, Hogger P, Rabe KF, et al. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 10:1496-1499, 1997.
46. Purucker M, Rosebraugh CJ, Zhou F, et al. Inhaled fluticasone propionate by diskus in the treatment of asthma: A comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 124:1584-1593, 2003.
47. Wieslander E, Delander EL, Jarkelid L, et al. Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro. Am J Respir Crit Care Med 19:477-484, 1998.
48. Nave R, Meyer W, Fuhst R, et al. Formation of fatty acid conjugates of clclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pul Pharmacol Ther 18:390-396, 2005.
49. Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 116:1206-1212, 2005.
50. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 114:1288-1293, 2004.
51. Vander Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 106:1209-1226, 2000.
52. Physicians Desk Reference, 58th ed. Montvale, NJ: Thompson Publishing, 1504-1507, 2004.
53. Nave R, Zech K, and Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharm 61:203-208, 2005.
54. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharm 45:146-152, 2005.
55. Chrousos GP, Ghaly L, Shedden A, et al. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 128:70-77, 2005.
56. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 165:1377-1383, 2002.
57. Rohatgi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, cliclesonide. Am J Therapeutics 12:201-209, 2005.
58. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 87:2160-2163, 2002.
59. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94:465-472, 2005.
60. Szefler S, Rohatgi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 128:1104-1114, 2005.
61. Lee DKC, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 127:851-860, 2005.
62. Agertoft L, and Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 115:940-945, 2005.